Lauric acid: Its role in behavioral modulation, neuro-inflammatory and oxidative stress markers in haloperidol induced Parkinson's disease

被引:21
作者
Zaidi, Awais Ali [1 ]
Khan, Mahtab Ahmad [1 ,2 ]
Shahreyar, Zaib Ali [1 ]
Ahmed, Hammad [1 ]
机构
[1] Univ Lahore, Fac Pharm, Dept Pharmacol, Lahore, Pakistan
[2] Univ Cent Punjab, Fac Pharm, Lahore, Pakistan
关键词
Parkinson's disease; dopamine; substantia nigra; neuro-inflammation; reactive oxygen species; RAT MODEL;
D O I
10.36721/PJPS.2020.33.2.SUP.755-763.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study was designed to investigate the neuro-protection of lauric acid (LA) on haloperidol (HPD) induced Parkinson's disease (PkD) rat model. Rats were divided into group A (normal), group B (diseased, by HPD lmg/kg i.p. for 14 days), group C (standard treatment, levodopa 30 mg/kg), group D (vehicle coconut oil 1ml/kg), group E (LA 0.66mg/kg) and group F (LA 1.32mg/kg) for 35 days after induction of PkD. The study displayed a state of oxidative stress in the striatum of rat model of PkD as shown from the increased MDA, NO levels and the decreased superoxide dismutase levels. HPD caused an increase in tumor necrosis factor-alpha level, NF-kappa B, IL-8 mRNA expression and suppress IL-4 expression. Neuro-protection with LA attenuated the oxidative stress and changes in pro-inflammatory cytokines induced due to PkD induction. The LA treatment also showed improvement in the histo -pathology of the rats' brain. LA also improved behavioral performances, food intake, weight gain as compared to animal of diseased group and prevented decline in motor activities (assessed Rotarod, and Beam walking test). LA showed significant neuro-protection against oxidative stress, inflammatory cytokines and behavioral changes in HPD induced rat model of PkD.
引用
收藏
页码:755 / 763
页数:9
相关论文
共 25 条
[1]   Role of mitochondrial ROS in the brain: from physiology to neurodegeneration [J].
Angelova, Plamena R. ;
Abramov, Andrey Y. .
FEBS LETTERS, 2018, 592 (05) :692-702
[2]   Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next? [J].
Bartus, Raymond T. ;
Johnson, Eugene M., Jr. .
NEUROBIOLOGY OF DISEASE, 2017, 97 :169-178
[3]   Recovery of Motor Deficit, Cerebellar Serotonin and Lipid Peroxidation Levels in the Cortex of Injured Rats [J].
Bueno-Nava, Antonio ;
Gonzalez-Pina, Rigoberto ;
Alfaro-Rodriguez, Alfonso ;
Nekrassov-Protasova, Vladimir ;
Durand-Rivera, Alfredo ;
Montes, Sergio ;
Ayala-Guerrero, Fructuoso .
NEUROCHEMICAL RESEARCH, 2010, 35 (10) :1538-1545
[4]  
Cheema MAR, 2018, NUTR NEUROSCI, V21, P185, DOI [10.1080/1028415x.2016.1257417, 10.1080/1028415X.2016.1257417]
[5]   Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease [J].
Deleu, D ;
Northway, MG ;
Hanssens, Y .
CLINICAL PHARMACOKINETICS, 2002, 41 (04) :261-309
[6]   How common are the "common" neurologic disorders? [J].
Hirtz, D. ;
Thurman, D. J. ;
Gwinn-Hardy, K. ;
Mohamed, M. ;
Chaudhuri, A. R. ;
Zalutsky, R. .
NEUROLOGY, 2007, 68 (05) :326-337
[7]  
Holloway RG, 2004, ARCH NEUROL-CHICAGO, V61, P1044
[8]   Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine(MPTP) Intoxication [J].
Hutter-Saunders, Jessica A. L. ;
Gendelman, Howard E. ;
Mosley, R. Lee .
JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2012, 7 (01) :279-288
[9]   Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats [J].
Jin, Feng ;
Wu, Qin ;
Lu, Yuan-Fu ;
Gong, Qi-Hai ;
Shi, Jing-Shan .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 600 (1-3) :78-82
[10]   Metals, oxidative stress and neurodegenerative disorders [J].
Jomova, Klaudia ;
Vondrakova, Dagmar ;
Lawson, Michael ;
Valko, Marian .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2010, 345 (1-2) :91-104